PRICE T ROWE ASSOCIATES INC /MD/

Holdings History for Monte Rosa Therapeutics, Inc. - Common Stock, $0.0001 par value per share (GLUE)

Symbol: GLUE on Nasdaq
Investment type: Equity / Common Stock, $0.0001 par value per share
Latest Disclosed Shares Owned: 4,637,060 shares
Security Ownership %: 7.5%

Shares, Excluding Options vs Price

Value, Excluding Options

T. Rowe Price Associates, Inc. ownership in Monte Rosa Therapeutics, Inc. Common Stock, $0.0001 par value per share (GLUE)

14 Nov 2025 - T. Rowe Price Associates, Inc. has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 4,637,060 shares of Monte Rosa Therapeutics, Inc. Common Stock, $0.0001 par value per share (GLUE). This represents 7.5% ownership of the company. This is the first filing by PRICE T ROWE ASSOCIATES INC /MD/ disclosing ownership of Monte Rosa Therapeutics, Inc. Common Stock, $0.0001 par value per share (GLUE).

Reporting Name	Ownership %	Change	Value $	Shares owned	Change	Activity %	Price	Form	Report date	Filing time
T. Rowe Price Associates, Inc.	7.5%		$34,360,615	4,637,060			$7.41	13G/A	30 Sep 2025	14 Nov 2025, 12:19

Holdings date	Weight	Change	Value $	Shares	Change	Activity %	Price	All Holders
31 Dec 2025	0.01%	+0%	$80,265,000	5,118,904	+481,844	+10%	$15.68	Q4 2025
30 Sep 2025	0%	-0%	$34,362,000	4,637,060	-1,688,598	-27%	$7.41	Q3 2025
30 Jun 2025	0%	-0%	$28,529,000	6,325,658	-318,478	-4.8%	$4.51	Q2 2025
31 Mar 2025	0%	-0%	$30,830,000	6,644,136	-472,501		$4.64	Q1 2025
31 Dec 2024	0.01%	+0%	$49,391,000	7,116,637	+515,496	+7.8%	$6.94	Q4 2024
30 Sep 2024	0%	+0%	$34,987,000	6,601,141	+623,554	+10%	$5.30	Q3 2024
30 Jun 2024	0%	+0%	$22,357,000	5,977,587	+880,800	+17%	$3.74	Q2 2024
31 Mar 2024	0%	+0%	$35,933,000	5,096,787	+155,880	+3.2%	$7.05	Q1 2024
31 Dec 2023	0%	+0%	$27,917,000	4,940,907	+1,070,360	+28%	$5.65	Q4 2023
30 Sep 2023	0%	-0%	$18,541,000	3,870,547	-25,951	-0.67%	$4.79	Q3 2023
30 Jun 2023	0%	+0%	$26,692,000	3,896,498	+203,004	+5.5%	$6.85	Q2 2023
31 Mar 2023	0%	+0%	$28,773,000	3,693,494	+10,064	+0.27%	$7.79	Q1 2023
31 Dec 2022	0%	-0%	$28,031,000	3,683,430	-79,956	-2.1%	$7.61	Q4 2022
30 Sep 2022	0.01%	-0%	$30,747,000	3,763,386	-1,485,749	-28%	$8.17	Q3 2022
30 Jun 2022	0.01%	-0%	$50,759,000	5,249,135	-101,788	-1.9%	$9.67	Q2 2022
31 Mar 2022	0.01%	+0%	$75,020,000	5,350,923	+1,204,004	+29%	$14.02	Q1 2022
31 Dec 2021	0.01%	+0%	$84,680,000	4,146,919	+999,985	+32%	$20.42	Q4 2021
30 Sep 2021	0.01%	+0%	$69,262,000	3,146,934	+409,280	+15%	$22.01	Q3 2021
30 Jun 2021	0.01%	+0.01%	$61,277,000	2,737,654	+2,737,654	NEW	$22.38	Q2 2021

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.